Epizyme, Inc. (NASDAQ:EPZM) insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction on Monday, July 24th. The stock was sold at an average price of $13.44, for a total transaction of $201,600.00. Following the completion of the sale, the insider now owns 22,228 shares of the company’s stock, valued at $298,744.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
Peter Tai-Ching Ho also recently made the following trade(s):
- On Monday, June 26th, Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock. The stock was sold at an average price of $14.87, for a total transaction of $223,050.00.
- On Thursday, May 25th, Peter Tai-Ching Ho sold 15,000 shares of Epizyme stock. The stock was sold at an average price of $16.11, for a total transaction of $241,650.00.
Epizyme, Inc. (NASDAQ:EPZM) opened at 13.85 on Thursday. Epizyme, Inc. has a 52-week low of $7.02 and a 52-week high of $18.50. The firm’s market cap is $809.75 million. The company has a 50-day moving average of $13.72 and a 200 day moving average of $14.49.
Epizyme (NASDAQ:EPZM) last announced its earnings results on Friday, August 4th. The biopharmaceutical company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.08. The business had revenue of $10 million during the quarter, compared to the consensus estimate of $3.95 million. Epizyme had a negative net margin of 1,376.33% and a negative return on equity of 63.10%. Epizyme’s revenue was up 2027.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.49) EPS. On average, equities research analysts anticipate that Epizyme, Inc. will post ($2.39) EPS for the current year.
TRADEMARK VIOLATION WARNING: “Peter Tai-Ching Ho Sells 15,000 Shares of Epizyme, Inc. (NASDAQ:EPZM) Stock” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this report can be read at https://stocknewstimes.com/2017/08/17/peter-tai-ching-ho-sells-15000-shares-of-epizyme-inc-nasdaqepzm-stock-updated-updated.html.
A number of hedge funds have recently modified their holdings of EPZM. Legal & General Group Plc boosted its stake in shares of Epizyme by 8.9% in the first quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock valued at $165,000 after buying an additional 795 shares during the period. UBS Asset Management Americas Inc. acquired a new stake in shares of Epizyme during the first quarter valued at $175,000. BB&T Securities LLC acquired a new stake in shares of Epizyme during the second quarter valued at $181,000. Trexquant Investment LP acquired a new stake in shares of Epizyme during the second quarter valued at $184,000. Finally, SG Americas Securities LLC boosted its stake in shares of Epizyme by 83.3% in the second quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock valued at $202,000 after buying an additional 6,072 shares during the period. Institutional investors and hedge funds own 81.24% of the company’s stock.
A number of research firms have issued reports on EPZM. Oppenheimer Holdings, Inc. set a $26.00 price target on shares of Epizyme and gave the company a “buy” rating in a report on Monday, June 5th. Zacks Investment Research upgraded shares of Epizyme from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a report on Tuesday, May 16th. HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Epizyme in a report on Wednesday, June 7th. Royal Bank Of Canada set a $20.00 price target on shares of Epizyme and gave the company a “buy” rating in a report on Monday, June 12th. Finally, Cann reaffirmed a “buy” rating and set a $26.00 price objective on shares of Epizyme in a research report on Tuesday, April 25th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eleven have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $23.38.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
